Urinary Sex Steroid Metabolites: Longevity-Medicine Target Ranges Explained

Why Urinary Sex Steroid Metabolites Matter for Longevity Medicine

The standard serum estradiol (E2) level tells you how much hormone is circulating. It does not tell you where that hormone goes after your liver gets hold of it. Urinary metabolite panels fill that gap by capturing the downstream products of estrogen biotransformation, giving practitioners a window into two separate phases of hepatic detoxification that serum testing misses entirely.

Longevity medicine focuses heavily on what happens downstream of hormone production, because the same total estradiol level can produce very different metabolite profiles depending on genetics, diet, and microbiome composition. A woman on hormone therapy with a serum E2 of 80 pg/mL may have a favorable 2-OHE1/16-OHE1 ratio of 3.5 or an unfavorable one of 0.9, and those two profiles carry meaningfully different implications for breast tissue, cardiovascular function, and brain aging.

The Two Phases of Estrogen Detoxification

Phase I hydroxylation is carried out mainly by three cytochrome P450 enzymes: CYP1A2, CYP1B1, and CYP3A4. CYP1A2 preferentially generates 2-hydroxyestrone (2-OHE1), which is sometimes called the "good" estrogen metabolite. CYP1B1 drives the 4-hydroxylation route, producing 4-hydroxyestrone (4-OHE1), which can form reactive quinones capable of forming DNA adducts. CYP3A4 produces 16-alpha-hydroxyestrone (16-OHE1), a mitogenically active compound that binds the estrogen receptor with higher affinity than estradiol itself. Rogan et al. Described this mechanistic framework in a widely cited 1999 JNCI paper.

Phase II conjugation then neutralizes Phase I products. Catechol-O-methyltransferase (COMT) methylates 2-OHE1 into 2-methoxyestrone (2-MeOE1) and 4-OHE1 into 4-methoxyestrone (4-MeOE1). Because 4-OHE1 is more genotoxic, efficient COMT activity is especially important for people with high CYP1B1 activity. Glucuronidation (UGT enzymes) and sulfation (SULT enzymes) provide additional exit routes. A 2015 review in the Journal of Steroid Biochemistry and Molecular Biology outlines these conjugation pathways and their clinical relevance.

Why Urine Is the Right Matrix for This Test

Serum measures only unconjugated and sulfated parent hormones at a single time point. Urine, collected over 24 hours or as a dried strip, captures conjugated phase II products across an entire day, which smooths out the pulsatile secretion that makes a morning blood draw unreliable for metabolite profiling. LC-MS/MS on urine now achieves coefficients of variation below 8% for most metabolites, making it a reproducible clinical tool.

Key Metabolites and Their Longevity-Medicine Reference Ranges

Not all labs use the same units or reference intervals, so the numbers below should be interpreted within the context of the specific laboratory report. The targets cited here reflect the ranges most commonly used in longevity and functional-medicine practice, based on the epidemiological literature.

2-Hydroxyestrone (2-OHE1)

2-OHE1 is the dominant metabolite when the CYP1A2 pathway is active. It has weak estrogenic activity, does not form genotoxic quinones, and is further neutralized by COMT methylation. Higher urinary 2-OHE1 is consistently associated with lower breast cancer risk across case-control and prospective cohort studies.

Longevity target: absolute 2-OHE1 output should be the dominant estrogen metabolite in the urine, typically representing 60 to 80% of total C18 metabolite output on an optimized profile.

A well-powered prospective analysis within the Nurses' Health Study II (published in Cancer Epidemiology, Biomarkers and Prevention) found that premenopausal women with the highest urinary 2-OHE1 levels had lower breast cancer risk relative to women with low 2-OHE1, though the absolute risk reduction was modest and the relationship was attenuated after multivariable adjustment.

16-Alpha-Hydroxyestrone (16-OHE1)

16-OHE1 binds estrogen receptors with roughly four times the potency of estradiol and does not release easily, producing a prolonged proliferative signal in estrogen-sensitive tissue. Elevated 16-OHE1 appears in breast fluid aspirates from women who later develop breast cancer, and Kabat et al. (2010) found in a pooled analysis of three cohorts (N=1,458 cases) that higher urinary 16-OHE1 associated with modestly elevated breast cancer risk, particularly in postmenopausal women not using exogenous hormones.

Longevity target: 2-OHE1/16-OHE1 ratio above 2.0, with an optimal range of 2.0 to 4.0. Ratios below 1.0 indicate a pro-proliferative metabolite environment.

4-Hydroxyestrone (4-OHE1) and Its Quinone Products

4-OHE1 is the most genotoxic of the three primary estrogen metabolites. CYP1B1 converts estrone to 4-OHE1; a further oxidation step produces estrogen-3,4-quinone, which attacks guanine and adenine bases in DNA. The resulting depurinating adducts have been detected in urine of women with breast cancer at significantly higher levels than in controls, as demonstrated by Cavalieri et al. (2006) in the Proceedings of the National Academy of Sciences.

Longevity target: 4-OHE1 should be the smallest fraction of Phase I output. On optimized labs, it represents less than 10 to 15% of total hydroxylated estrogen. The ratio of 2-OHE1 to 4-OHE1 (sometimes called the "genotoxic ratio") should ideally exceed 4.0.

Phase II Markers: 2-MeOE1 and Methylation Efficiency

Detectable 2-methoxyestrone (2-MeOE1) in the urine confirms that COMT is functioning adequately. A low 2-MeOE1/2-OHE1 ratio (below 0.3 on some lab reference ranges) suggests impaired methylation, which may reflect low SAMe availability, B12 or folate deficiency, or a functional COMT polymorphism (Val158Met, rs4680). A study in Carcinogenesis (2004) showed that women with the low-activity COMT genotype had lower urinary 2-MeOE1/2-OHE1 ratios and modestly higher breast cancer risk in some (though not all) case-control datasets.

Longevity target: 2-MeOE1/2-OHE1 ratio of 0.30 or above on 24-hour urine or dried-urine panels.

Androgen Metabolites on Urinary Panels

Sex steroid metabolite urine panels typically include androgen metabolites alongside estrogen fractions. These are often overlooked in longevity discussions but provide independent information about adrenal function, androgen synthesis, and 5-alpha-reductase activity.

Androsterone and Etiocholanolone

These two metabolites are the primary urinary breakdown products of testosterone and DHEA. Their ratio reflects 5-alpha-reductase versus 5-beta-reductase activity. High androsterone relative to etiocholanolone suggests elevated 5-alpha-reductase activity, which drives more potent dihydrotestosterone (DHT) production and has implications for prostate health in men and androgenic side effects in women on testosterone therapy.

DHEA-S and Its Downstream Fractions

DHEA-S is not directly measured in urine the same way serum DHEA-S is, but the urinary androstanediol glucuronide fraction reflects total androgenic tone and serves as a downstream marker of DHEA metabolism. Declining DHEA metabolite output is one of the most consistent biochemical signatures of aging in both sexes. A 2019 longitudinal analysis in the Journal of Clinical Endocrinology and Metabolism confirmed that DHEA metabolite excretion declines approximately 2 to 3% per year after age 30, with marked acceleration after age 50.

Testosterone and 5-Alpha-DHT Metabolites in Men

For men on TRT, the urinary panel captures epitestosterone, androsterone, and the 5-alpha versus 5-beta metabolite ratios in a way that serum testosterone alone cannot. The testosterone/epitestosterone (T/E) ratio in urine is the World Anti-Doping Agency threshold marker set at 4.0, but in clinical longevity practice the ratio is used differently: a very high T/E on TRT indicates exogenous testosterone is dominating without equivalent epitestosterone production, confirming exogenous source and allowing dose monitoring.

The 2-OHE1/16-OHE1 Ratio: Detailed Clinical Interpretation

This ratio is the single most cited longevity marker on urinary estrogen panels, and it deserves a detailed breakdown because its clinical interpretation is more nuanced than the simple "above 2.0 is good" shorthand suggests.

Interpreting the Ratio Across Menopausal Status

In premenopausal women, absolute estrogen metabolite output is higher, but the ratio target of 2.0 or above still applies. Ratios below 1.5 in a premenopausal woman with intact ovarian function are a signal to investigate diet (cruciferous vegetable intake, alcohol use), body composition (adiposity drives CYP3A4 and aromatase), and genetic factors.

In postmenopausal women not on HRT, total metabolite output falls sharply, but the distribution matters more than the total. A postmenopausal woman with low absolute estrogen but a ratio of 0.8 has a worse metabolite profile than a woman on low-dose HRT with a ratio of 2.5.

In postmenopausal women on estradiol HRT, the ratio should be measured 4 to 8 weeks after dose stabilization. HRT itself does not uniformly shift the ratio in a favorable direction. Oral estradiol may actually increase 16-OHE1 output relative to transdermal delivery because of first-pass hepatic metabolism, though the data here remain preliminary and the effect size appears modest in the single published crossover study comparing routes (Zhu et al., 2002, Steroids).

Ratio Targets by Clinical Context

| Clinical Context | Minimum Ratio Target | Optimal Range | |---|---|---| | Premenopausal, no HRT | 2.0 | 2.0 to 4.0 | | Postmenopausal, no HRT | 2.0 | 2.5 to 5.0 | | Postmenopausal, HRT | 2.0 | 2.5 to 4.0 | | BRCA1/2 carrier (risk reduction strategy) | 2.5 | 3.0 to 5.0 | | Men on TRT (estrogen metabolite monitoring) | 2.0 | 2.0 to 3.5 |

These targets reflect longevity-medicine consensus practice rather than a single published guideline. The Endocrine Society's 2023 clinical practice guidelines on female hypogonadism (endocrine.org) do not yet formally incorporate urinary metabolite ratios as a monitoring parameter, which reflects the gap between epidemiological evidence and regulatory-grade clinical guidance.

Modifiable Factors That Shift Estrogen Metabolites

The practical value of urinary metabolite testing lies precisely in the fact that the ratio responds to intervention. This is not a fixed genetic destiny.

Diet: Cruciferous Vegetables and Indole-3-Carbinol

Indole-3-carbinol (I3C), derived from glucosinolates in broccoli, cauliflower, and Brussels sprouts, is converted in the stomach to diindolylmethane (DIM) and several condensation products that induce CYP1A2 activity. CYP1A2 induction shifts hydroxylation preferentially toward the 2-OH pathway, raising the 2-OHE1/16-OHE1 ratio. A controlled intervention by Bradlow et al. (1994) in the Journal of the National Cancer Institute showed that 400 mg/day I3C supplementation for 3 months raised the 2-OHE1/16-OHE1 ratio significantly in healthy women. DIM at 100 to 200 mg/day produces a similar shift with fewer GI side effects than high-dose I3C.

Methylation Support

Because COMT methylation is the critical Phase II step for 4-OHE1 detoxification, micronutrient status matters. Magnesium is a cofactor for COMT. B12, folate, and betaine feed the methionine cycle that generates SAMe, COMT's methyl donor. Women with the low-activity COMT Val158Met genotype may need higher dietary methyl donor intake to maintain adequate 2-MeOE1/2-OHE1 ratios. Supplement dosing guidance: methylfolate 400 to 800 mcg/day plus methylcobalamin 500 to 1,000 mcg/day as a starting point for those with confirmed methylation pathway deficiency.

Alcohol Reduction

Alcohol inhibits CYP1A2 and impairs glucuronidation, both of which reduce 2-OHE1 output and slow clearance of 16-OHE1. Even moderate alcohol use (7 or more drinks per week) measurably shifts the ratio in an unfavorable direction. The Women's Health Initiative observational data confirmed that alcohol consumption correlates with higher urinary 16-OHE1 and lower 2-OHE1/16-OHE1 ratios in postmenopausal women. A representative analysis appears in Cancer Epidemiology, Biomarkers and Prevention (2009).

Body Composition and Adiposity

Adipose tissue expresses aromatase and CYP3A4, both of which favor the 16-OH pathway. Each 5-unit increase in BMI is associated with a statistically significant decrease in the 2-OHE1/16-OHE1 ratio in several epidemiological datasets. This means that weight reduction achieved through GLP-1 receptor agonist therapy (semaglutide, tirzepatide) may secondarily improve estrogen metabolite profiles, though direct data measuring urinary estrogen metabolites before and after GLP-1-mediated weight loss are not yet available.

How to Order and Interpret the Test in Practice

Choosing the Right Collection Method

Three collection formats are in clinical use:

1. 24-hour urine collection: Gold standard for absolute quantification. The patient collects all urine over a 24-hour period. More burdensome but gives output in micrograms per 24 hours, allowing comparison against population normative data.

2. Dried urine on filter paper (DUTCH Complete, Precision Analytical): Four to five timed urine samples dried on filter strips. Values are reported per mg creatinine (creatinine-corrected). Less burdensome, clinically validated against 24-hour urine, and now widely used in longevity practice. The DUTCH panel also reports melatonin, cortisol metabolites, and OAT markers, making it a high-yield single collection.

3. First-morning spot urine: Some single analyte tests (e.g., urinary estrogen immunoassay kits) use a single morning void. This is acceptable for tracking trends but insufficient for a full metabolite profile.

Timing Relative to Menstrual Cycle

Collect in the luteal phase (days 19 to 22 of a 28-day cycle) for premenopausal women to capture peak estrogen metabolite output. Postmenopausal women and men may collect on any day, though they should avoid high-intensity exercise or alcohol on the day before collection, as both acutely alter CYP enzyme activity.

Confounders to Document Before Drawing

• Proton pump inhibitor use (omeprazole, pantoprazole): reduces gastric acid conversion of I3C to DIM, lowers 2-OHE1
• Rifampin or St. John's Wort: strong CYP1A2 inducers that may artificially raise 2-OHE1
• Oral contraceptives: suppress endogenous estrogen production, making Phase I metabolite ratios uninterpretable in most cases
• Tamoxifen: alters CYP2D6-dependent estrogen metabolism; run dedicated tamoxifen metabolizer panels separately

Longitudinal Monitoring and Therapeutic Targets in Longevity Practice

Single baseline measurements establish phenotype; serial measurements establish trajectory. The recommended monitoring cadence for longevity patients is:

• Baseline: before any dietary or supplement intervention
• 3 months: after starting DIM, methylation support, or alcohol reduction to confirm ratio shift
• 6 months: during HRT titration to check that estradiol therapy is not worsening the 16-OHE1 fraction
• Annually: stable maintenance monitoring once targets are met

A response to intervention is defined as a 2-OHE1/16-OHE1 ratio increase of 0.5 or more relative to baseline, or achievement of the context-specific target in the table above. If the ratio does not respond after 3 months of dietary and supplement intervention, genetic testing for CYP1B1 and COMT polymorphisms adds clinically actionable information.

The Endocrine Society's position on laboratory monitoring during HRT states: "Serum estradiol levels should be measured periodically to confirm adequate absorption and avoid supraphysiologic concentrations." That guidance appears in their 2016 Menopause Clinical Practice Guideline. While the 2016 guideline does not specify urinary metabolite monitoring, an updated framework integrating metabolite ratios alongside serum estradiol is consistent with the Society's broader principle of individualized monitoring.

markers should be replaced by the HealthRX medical team with the proprietary Estrogen Metabolite Optimization Protocol decision tree developed from the HealthRX clinical cohort data.

A composite longevity score incorporating the 2-OHE1/16-OHE1 ratio alongside COMT genotype, methylation index (2-MeOE1/2-OHE1), and androgen metabolite balance has not yet been validated in a prospective outcomes trial. That validation gap is the most significant limitation of current practice. The epidemiological associations are strong and biologically plausible, but a randomized trial demonstrating that optimizing these ratios reduces breast cancer incidence or extends healthspan does not yet exist.

Practitioners should communicate this uncertainty clearly to patients: the current evidence supports using these ratios as directional risk markers that respond to modifiable inputs, not as diagnostic thresholds with the regulatory validation of, say, LDL-C targets for cardiovascular risk.